(CL) Colgate-Palmolive - NYSE
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 71.529m USD | Total Return: 1.8% in 12m
Avg Turnover: 481M
EPS Trend: 89.2%
Qual. Beats: -1
Rev. Trend: 89.8%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Colgate-Palmolive Company (CL) is a global consumer goods manufacturer operating in two primary segments: Oral, Personal and Home Care, and Pet Nutrition. The company manages an extensive portfolio of established brands, including Colgate, Palmolive, Hills Science Diet, and Ajax, distributed through retail, professional, and eCommerce channels. Founded in 1806, the firm maintains a significant international footprint with sales spanning traditional household essentials and specialized therapeutic pet products.
The company operates within the consumer staples sector, a category characterized by defensive qualities due to the consistent demand for daily hygiene and cleaning products regardless of economic cycles. Its business model relies heavily on brand equity and a dual-track distribution strategy that targets both end-consumers and professional gatekeepers, such as dentists and veterinarians, to drive long-term loyalty. Investors may find it useful to examine the companys historical valuation trends on ValueRay.
- Emerging market demand drives organic sales growth in Oral Care segment
- Raw material and packaging costs impact gross profit margin stability
- Hill’s Pet Nutrition expansion increases high-margin revenue contribution
- Foreign exchange fluctuations affect reported earnings from international operations
- Strategic pricing actions offset inflationary pressures on manufacturing and logistics
| Net Income: 2.09b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 1.85 > 1.0 |
| NWC/Revenue: 0.71% < 20% (prev -5.25%; Δ 5.96% < -1%) |
| CFO/TA 0.26 > 3% & CFO 4.34b > Net Income 2.09b |
| Net Debt (7.12b) to EBITDA (5.05b): 1.41 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (805.1m) vs 12m ago -2.12% < -2% |
| Gross Margin: 60.06% > 18% (prev 60.73%; Δ -0.67% > 0.5%) |
| Asset Turnover: 125.1% > 50% (prev 119.8%; Δ 5.24% > 0%) |
| Interest Coverage Ratio: 16.70 > 6 (EBIT TTM 4.41b / Interest Expense TTM 264.0m) |
| A: 0.01 (Total Current Assets 6.08b - Total Current Liabilities 5.93b) / Total Assets 16.6b |
| B: 1.61 (Retained Earnings 26.8b / Total Assets 16.6b) |
| C: 0.27 (EBIT TTM 4.41b / Avg Total Assets 16.6b) |
| D: 0.01 (Book Value of Equity 145.0m / Total Liabilities 16.1b) |
| Altman-Z'' = 7.11 = AAA |
| DSRI: 1.05 (Receivables 1.89b/1.73b, Revenue 20.8b/19.9b) |
| GMI: 1.01 (GM 60.73% / 60.06%) |
| AQI: 0.92 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 1.04 (Revenue 20.8b / 19.9b) |
| TATA: -0.14 (NI 2.09b - CFO 4.34b) / TA 16.6b) |
| Beneish M = -3.00 (Cap -4..+1) = AA |
As of June 15, 2026, the stock is trading at USD 89.45 with a total of 2,851,072 shares traded.
Over the past week, the price has changed by +0.98%,
over one month by +0.69%,
over three months by -0.33% and
over the past year by +1.78%.
Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefore, it is recommended to hold CL.
- StrongBuy: 7
- Buy: 6
- Hold: 7
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 95.8 | 7.1% |
P/E Trailing = 34.6473
P/E Forward = 23.3645
P/S = 3.4397
P/B = 496.3933
P/EG = 1.6113
Revenue TTM = 20.8b USD
EBIT TTM = 4.41b USD
EBITDA TTM = 5.05b USD
Long Term Debt = 7.94b USD (from longTermDebt, last quarter)
Short Term Debt = 36.0m USD (from shortTermDebt, last quarter)
Debt = 8.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 566.0m
Net Debt = 7.12b USD (calculated: Debt 8.54b - CCE 1.42b)
Enterprise Value = 78.6b USD (71.5b + Debt 8.54b - CCE 1.42b)
Interest Coverage Ratio = 16.70 (Ebit TTM 4.41b / Interest Expense TTM 264.0m)
EV/FCF = 20.88x (Enterprise Value 78.6b / FCF TTM 3.77b)
FCF Yield = 4.79% (FCF TTM 3.77b / Enterprise Value 78.6b)
FCF Margin = 18.11% (FCF TTM 3.77b / Revenue TTM 20.8b)
Net Margin = 10.04% (Net Income TTM 2.09b / Revenue TTM 20.8b)
Gross Margin = 60.06% ((Revenue TTM 20.8b - Cost of Revenue TTM 8.30b) / Revenue TTM)
Gross Margin QoQ = 60.59% (prev 60.15%)
Tobins Q-Ratio = 4.74 (Enterprise Value 78.6b / Total Assets 16.6b)
Interest Expense / Debt = 3.09% (Interest Expense 264.0m / Debt 8.54b)
Taxrate = 26.12% (783.0m / 3.00b)
NOPAT = 3.26b (EBIT 4.41b * (1 - 26.12%))
Current Ratio = 1.02 (Total Current Assets 6.08b / Total Current Liabilities 5.93b)
Debt / Equity = 58.89 (Debt 8.54b / totalStockholderEquity, last quarter 145.0m)
Debt / EBITDA = 1.41 (Net Debt 7.12b / EBITDA 5.05b)
Debt / FCF = 1.89 (Net Debt 7.12b / FCF TTM 3.77b)
Total Stockholder Equity = 700.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.55% (Net Income 2.09b / Total Assets 16.6b)
RoE = 298.1% (Net Income TTM 2.09b / Total Stockholder Equity 700.0m)
RoCE = 51.06% (EBIT 4.41b / Capital Employed (Equity 700.0m + L.T.Debt 7.94b))
RoIC = 33.69% (NOPAT 3.26b / Invested Capital 9.67b)
WACC = 4.82% (E(71.5b)/V(80.1b) * Re(5.12%) + D(8.54b)/V(80.1b) * Rd(3.09%) * (1-Tc(0.26)))
Discount Rate = 5.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -87.41 | Cagr: -1.08%
[DCF] Terminal Value 76.51% ; FCFF base≈3.65b ; Y1≈3.92b ; Y5≈4.77b
[DCF] Fair Price = 82.59 (EV 73.2b - Net Debt 7.12b = Equity 66.1b / Shares 800.2m; r=8.35% [WACC [floored]]; 5y FCF grow 8.65% → 2.50% )
EPS Correlation: 89.22 | EPS CAGR: 6.89% | SUE: -4.0 | # QB: -1
Revenue Correlation: 89.83 | Revenue CAGR: 2.88% | SUE: 2.14 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.95 | Chg30d=-0.08% | Revisions=-68% | Analysts=16
EPS next Quarter (2026-09-30): EPS=0.92 | Chg30d=-0.11% | Revisions=-78% | Analysts=16
EPS current Year (2026-12-31): EPS=3.81 | Chg30d=-0.18% | Revisions=-56% | GrowthEPS=+3.2% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=4.04 | Chg30d=-0.22% | Revisions=-56% | GrowthEPS=+6.1% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -78%